Dear Partners,

The first quarter of 2021 was concluded with signs of optimism and gradual recovery in many countries across the globe. Still, despite the overall optimism supported by increase in vaccine production by leading pharmaceutical companies, COVID19 is still present and reaching new negative records in some countries.

From a cataract stand point, efforts are made in clinics and hospital settings to create a safe and controlled environment, and by doing so minimizing patients’ exposure, facilitating a growing number of surgeries and returning, in some markets, to the pre pandemic volumes.

During this period, we continued supporting our partners in various aspects, frequent meetings, webinars, zoom training for surgeons and sales teams, these were the actions we took so that we can stay close to all our markets.

One of Hanita Lenses key success factors during this period was the INTENSITY technology, leading to growing numbers of satisfied patients and surgeons.

Near vision acuity and minimal halos and glare qualities of INTENSITY were repeatedly mentioned as unique features compared with other premium lenses. We have also learned in the process that close facilitation and monitoring is most important.

We plan to publish the full results of our unique technology in Q2

Concurrently, and in accordance with our strategic plan, we continue forwarding the development for our premium technologies, Intensity Toric and Full Range Toric both in hydrophilic material, as well as Intensity in Hydrophobic material.

I am also happy to report that during Q1 we have obtained CE mark for our new AssiAnchor.

Our outlook for Q2 is optimistic though realistic. With vaccination in place over multiple countries on the rise, we expect gradual recovery in most markets. I believe this will lead to a slow but steady removal of travel restrictions, allowing us to finally meet in person, participate in events, and reminding us all how it used to be in the “old days”.

With kind regards,

Yoram Gonen